You are here:
Home
NICE Guidance
Conditions and diseases
Cancer
Prostate cancer
Stockholm3 for prostate cancer screening
Medtech innovation briefing
Reference number:
MIB303
Published:
09 August 2022
Download (PDF)
Overview
Summary
The technology
Regulatory information
Equality considerations
Clinical and technical evidence
Expert comments
Patient organisation comments
Expert commentators
Development of this briefing
Regulatory information
Stockholm3 is CE-marked. The company intends to file for UKCA marking in July 2022.
Next page
Equality considerations
Previous page
The technology
Back to top